RECRUITING

Mitigating the Impact of Stigma and Shame Among People Living With HIV and Substance Use Disorders

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

People living with HIV and substance use disorders (SUDs) are less likely to be virally suppressed, which can lead to HIV transmission and negative health outcomes. This hybrid type 1 study will assess the efficacy, mechanisms, as well as facilitators and barriers to implementing the MATTER intervention, a virtually delivered 5-session text-enhanced psychobehavioral intervention designed to facilitate viral suppression by addressing internalized stigma and shame as barriers to engagement in HIV care among individuals living with HIV and SUDs in two locations with different levels of HIV resources (i.e., the Boston, Massachusetts and Miami, Florida metro areas). MATTER aims to mitigate the negative behavioral consequences of internalized stigma and shame on viral suppression by a) developing behavioral self-care goal setting skills and related self-efficacy, b) increasing metacognitive awareness (i.e., non-judgmental awareness of emotions and cognitions), and c) teaching and reinforcing compassionate self-restructuring (i.e., self- compassion), in addition to providing access to phone-based resource navigation. Scalable interventions such as MATTER are essential to our efforts to end the HIV epidemic in high priority regions.

Official Title

Mitigating the Impact of Stigma and Shame as a Barrier to Viral Suppression Among People Living With HIV and Substance Use Disorders

Quick Facts

Study Start:2025-03-20
Study Completion:2028-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05934305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * HIV+
  2. * Meet criteria for an illicit (not solely including tobacco, cannabis, or alcohol) SUD
  3. * Endorse internalized stigma related to HIV, substance use, sexual orientation, or gender-identity
  4. * Unsuppressed HIV VL (\>20 copies/mL).
  5. * Provide informed consent in English
  6. * Verbally communicate in English and read in English or Spanish
  7. * Be ≥18 years old
  8. * Provide evidence or documentation of HIV+ status
  9. * Release HIV-related health records
  10. * Have access to a cell phone with text capacity (study will supplement phones and plans as needed consistent with our pilot work).
  1. * Cisgender women
  2. * Cisgender heterosexual men

Contacts and Locations

Study Contact

Abigail Batchelder, PhD, MPH
CONTACT
6173587640
abatchel@bu.edu
Alexandria Miller, PhD
CONTACT
anmille1@bu.edu

Principal Investigator

Abigail Batchelder, PhD, MPH
PRINCIPAL_INVESTIGATOR
CABU School of Medicine, Psychiatry

Study Locations (Sites)

Florida International University
Miami, Florida, 33199
United States
Fenway Health
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Boston University

  • Abigail Batchelder, PhD, MPH, PRINCIPAL_INVESTIGATOR, CABU School of Medicine, Psychiatry

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-20
Study Completion Date2028-07

Study Record Updates

Study Start Date2025-03-20
Study Completion Date2028-07

Terms related to this study

Additional Relevant MeSH Terms

  • Hiv
  • Substance Use Disorders